2. Search Result
Search Result
Results for "

liver ischemia-reperfusion injury

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

3

Peptides

4

Natural
Products

5

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W006566
    5-AIQ

    5-Aminoisoquinolin-1-one

    		 PARP Cancer
    5-AIQ (5-Aminoisoquinolin-1-one) is a PARP-1 inhibitor. 5-AIQ is an important functional group in various drugs. 5-AIQ reduces the tissue injury associated with ischemia-reperfusion of the liver, it can be used for the research of the research conditions associated with ischemia-reperfusion of the liver .
    5-AIQ
  • HY-N0385
    Gomisin J
    3 Publications Verification

    		 NO Synthase AMPK CaMK NF-κB Keap1-Nrf2 Cardiovascular Disease Inflammation/Immunology
    Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc .
    Gomisin J
  • HY-13315
    Montelukast sodium
    10+ Cited Publications

    MK0476

    		 Leukotriene Receptor Inflammation/Immunology Cancer
    Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .
    Montelukast sodium
  • HY-13315A
    Montelukast
    10+ Cited Publications

    MK0476 free base

    		 Leukotriene Receptor Inflammation/Immunology Cancer
    Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .
    Montelukast
  • HY-P3211
    Nangibotide
    3 Publications Verification

    LR12

    		 TREM receptor NF-κB NOD-like Receptor (NLR) Interleukin Related Apoptosis Cardiovascular Disease Inflammation/Immunology
    Nangibotide (LR12) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide inhibits Apoptosis. Nangibotide reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .
    Nangibotide
  • HY-W006566A
    5-AIQ hydrochloride

    5-Aminoisoquinolin-1-one hydrochloride

    		 PARP Cancer
    5-AIQ hydrochloride is a PARP-1 inhibitor. 5-AIQ hydrochloride is an important functional group in various drugs. 5-AIQ hydrochloride reduces the tissue injury associated with ischemia-reperfusion of the liver, it can be used for the research of the research conditions associated with ischemia-reperfusion of the liver .
    5-AIQ hydrochloride
  • HY-134221
    S-Nitroso-N-acetylcysteine

    		Adrenergic Receptor Reactive Oxygen Species (ROS) Cardiovascular Disease
    S-Nitroso-N-acetylcysteine is a nitric oxide donor. S-Nitroso-N-acetylcysteine has a tissue vascular dilation effect, which can enhance liver microcirculation and effectively prevent ischemia-reperfusion injury in fatty liver. S-Nitroso-N-acetylcysteine can reduce liver fibrosis in rats with cirrhosis .
    S-Nitroso-N-acetylcysteine
  • HY-13315S
    Montelukast-d6

    MK0476-d6 free acid

    		 Isotope-Labeled Compounds Leukotriene Receptor Inflammation/Immunology
    Montelukast-d6 is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage .
    Montelukast-d6
  • HY-13315S1
    Montelukast-d6 sodium

    MK0476-d6

    		 Leukotriene Receptor Inflammation/Immunology
    Montelukast-d6 (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage .
    Montelukast-d6 sodium
  • HY-13315B
    Montelukast dicyclohexylamine

    MK0476 dicyclohexylamine

    		 Leukotriene Receptor Inflammation/Immunology Cancer
    Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .
    Montelukast dicyclohexylamine
  • HY-P10897
    SjDX5-271

    		Toll-like Receptor (TLR) NF-κB Cardiovascular Disease Inflammation/Immunology
    SjDX5-271 is a small 3 kDa peptide. SjDX5-271 inhibits the TLR4/MyD88/NF-κB signaling pathway. SjDX5-271 induces cell polarization. SjDX5-271 alleviats hepatic inflammation. SjDX5-271 protects mice against liver ischemia-reperfusion injury .
    SjDX5-271
  • HY-13315R
    Montelukast sodium (Standard)

    MK0476 (Standard)

    		 Reference Standards Leukotriene Receptor Inflammation/Immunology
    Montelukast (sodium) (Standard) is the analytical standard of Montelukast (sodium). This product is intended for research and analytical applications. Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .
    Montelukast sodium (Standard)
  • HY-110228
    Metformin-d6 hydrochloride

    1,1-Dimethylbiguanide-d6 hydrochloride

    		 AMPK Autophagy Mitophagy Apoptosis mTOR Cardiovascular Disease Metabolic Disease
    Metformin-d6 hydrochloride is a deuterium labeled Metformin hydrochloride. Metformin hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .
    Metformin-d6 hydrochloride
  • HY-P3211A
    Nangibotide TFA
    3 Publications Verification

    LR12 TFA

    		 TREM receptor NF-κB NOD-like Receptor (NLR) Interleukin Related Apoptosis Cardiovascular Disease Inflammation/Immunology
    Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .
    Nangibotide TFA
  • HY-B0627
    Metformin
    Maximum Cited Publications
    149 Publications Verification

    1,1-Dimethylbiguanide

    		 AMPK Autophagy Mitophagy Apoptosis mTOR Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .
    Metformin
  • HY-17471A
    Metformin hydrochloride
    Maximum Cited Publications
    149 Publications Verification

    1,1-Dimethylbiguanide hydrochloride

    		 AMPK Autophagy Mitophagy Apoptosis mTOR Cardiovascular Disease Metabolic Disease Cancer
    Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .
    Metformin hydrochloride
  • HY-13315AR
    Montelukast (Standard)

    MK0476 free base (Standard)

    		 Reference Standards Leukotriene Receptor Inflammation/Immunology
    Montelukast (Standard) is the analytical standard of Montelukast. This product is intended for research and analytical applications. Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .
    Montelukast (Standard)
  • HY-B0627A
    Metformin (glycinate)

    1,1-Dimethylbiguanide (glycinate)

    		 AMPK Autophagy Mitophagy Apoptosis mTOR Cardiovascular Disease Metabolic Disease Cancer
    Metformin (1,1-Dimethylbiguanide) glycinate inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin glycinate also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin glycinate regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .
    Metformin (glycinate)
  • HY-13315BR
    Montelukast dicyclohexylamine (Standard)

    MK0476 dicyclohexylamine (Standard)

    		 Reference Standards Leukotriene Receptor Inflammation/Immunology Cancer
    Montelukast (dicyclohexylamine) (Standard) is the analytical standard of Montelukast (dicyclohexylamine). This product is intended for research and analytical applications. Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .
    Montelukast dicyclohexylamine (Standard)
  • HY-17471AR
    Metformin hydrochloride (Standard)

    1,1-Dimethylbiguanide hydrochloride (Standard)

    		 Reference Standards AMPK Autophagy Mitophagy Apoptosis mTOR Cardiovascular Disease Metabolic Disease Cancer
    Metformin hydrochloride (Standard) is the analytical standard of Metformin (hydrochloride). This product is intended for research and analytical applications. Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .
    Metformin hydrochloride (Standard)
  • HY-B0627S
    Metformin-d6

    1,1-Dimethylbiguanide-d6

    		 Isotope-Labeled Compounds AMPK Autophagy Mitophagy Apoptosis mTOR Cardiovascular Disease
    Metformin-d6 (1,1-Dimethylbiguanide-d6) is a deuterated labeled Metformin (HY-B0627). Metformin inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .
    Metformin-d6
  • HY-B0627S1
    Metformin-13C2 hydrochloride

    1,1-Dimethylbiguanide-13C2 hydrochloride

    		 Isotope-Labeled Compounds AMPK Autophagy Mitophagy Apoptosis mTOR Cardiovascular Disease Metabolic Disease Cancer
    Metformin- 13C2 (1,1-Dimethylbiguanide- 13C2) hydrochloride is the 13C-labeled Metformin hydrochloride (HY-17471A). Metformin hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .
    Metformin-13C2 hydrochloride
  • HY-N6850
    Calenduloside E
    1 Publications Verification

    		 Apoptosis Pyroptosis AMPK Bcl-2 Family JAK STAT Calcium Channel Interleukin Related TNF Receptor SOD Reactive Oxygen Species (ROS) PPAR Cardiovascular Disease Inflammation/Immunology
    Calenduloside E is a pentacyclic triterpenoid saponin that can be extracted from the bark and roots of Aralia ovata, and has anti-inflammatory and anti-apoptotic activities. Calenduloside E alleviates atherosclerosis by regulating macrophage polarization, improves mitochondrial function by regulating the AMPK-SIRT3 pathway, and alleviates acute liver injury. In addition, Calenduloside E promotes the interaction between L-type calcium channels and Bcl-2 related apoptosis genes, inhibits calcium overload, and alleviates myocardial ischemia/reperfusion injury. Calenduloside E also improves non-alcoholic fatty liver disease by regulating heat shock-dependent pathways, and inhibits ROS mediated JAK1-STAT3 pathways to reduce cellular inflammatory responses .
    Calenduloside E
  • HY-N0806
    Sweroside
    1 Publications Verification

    		 Keap1-Nrf2 AMPK Sirtuin NF-κB NOD-like Receptor (NLR) Pyroptosis Apoptosis Autophagy PARP Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Sweroside is an iridoid glycoside that targets multiple targets, including the Keap1/Nrf2 axis, NLRP3 inflammasome, SIRT1, NF-κB, AMPK/mTOR pathway, and caspase family. Sweroside promotes Nrf2 nuclear translocation by competitively binding to Keap1. Sweroside also inhibits oxidative stress and NLRP3-mediated pyroptosis by activating Nrf2, inhibits NF-κB inflammatory pathway by activating SIRT1, and promotes autophagy and induces caspase-dependent apoptosis via the AMPK/mTOR pathway. Sweroside has antioxidant, anti-inflammatory, anti-apoptotic, and lipid metabolism regulating activities, and can be used in the research of myocardial ischemia-reperfusion injury, leukemia, acute lung injury, non-alcoholic fatty liver disease, and other fields .
    Sweroside
  • HY-E70291
    N-Acetylgalactosaminyltransferase 4

    GALNT4

    		 MAP3K p38 MAPK JNK NF-κB Endogenous Metabolite Cancer
    N-Acetylgalactosaminyltransferase 4 (GALNT4) is a glycosyltransferase capable of inhibiting the activation of ASK1. By directly binding to ASK1, N-Acetylgalactosaminyltransferase 4 suppresses its N-terminal dimerization and subsequent phosphorylation, leading to robust inactivation of downstream JNK/p38 and NF-κB signals, and thereby improving the prognosis of liver surgery .
    N-Acetylgalactosaminyltransferase 4
  • HY-N0806R
    Sweroside (Standard)

    		Reference Standards Keap1-Nrf2 AMPK Sirtuin NF-κB NOD-like Receptor (NLR) Pyroptosis Apoptosis Autophagy PARP Metabolic Disease
    Sweroside (Standard) is the analytical standard of Sweroside (HY-N0806). This product is intended for research and analytical applications. Sweroside is an iridoid glycoside that targets multiple targets, including the Keap1/Nrf2 axis, NLRP3 inflammasome, SIRT1, NF-κB, AMPK/mTOR pathway, and caspase family. Sweroside promotes Nrf2 nuclear translocation by competitively binding to Keap1. Sweroside also inhibits oxidative stress and NLRP3-mediated pyroptosis by activating Nrf2, inhibits NF-κB inflammatory pathway by activating SIRT1, and promotes autophagy and induces caspase-dependent apoptosis via the AMPK/mTOR pathway. Sweroside has antioxidant, anti-inflammatory, anti-apoptotic, and lipid metabolism regulating activities, and can be used in the research of myocardial ischemia-reperfusion injury, leukemia, acute lung injury, non-alcoholic fatty liver disease, and other fields .
    Sweroside (Standard)
  • HY-151488
    CypD-IN-4

    		Cyclophilin Neurological Disease Metabolic Disease Cancer
    CypD-IN-4 is a potent and subtype-selective cyclophilin D (CypD) inhibitor. CypD-IN-4 has CypD affinity with an IC50 value of 0.057 μM. CypD-IN-4 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes .
    CypD-IN-4
  • HY-151487
    CypD-IN-3

    		Cyclophilin Neurological Disease Metabolic Disease Cancer
    CypD-IN-3 is a potent and subtype-selective cyclophilin D (CypD) inhibitor. CypD-IN-3 has CypD affinity with an IC50 value of 0.01 μM. CypD-IN-3 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes .
    CypD-IN-3
  • HY-151489
    CypE-IN-1

    		Cyclophilin Neurological Disease Metabolic Disease Cancer
    CypE-IN-1 is a potent and subtype-selective cyclophilin E (CypE) inhibitor. CypE-IN-1 has CypE affinity with IC50 and Ki values of 0.013 μM and 0.072 μM, respectively. CypE-IN-1 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes .
    CypE-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: